Abstract
Osteoclasts are the only cells capable of breaking down bone matrix, and excessive activation of osteoclasts is responsible for bone-destructive diseases. In this study, we investigated the effects of decursin from extract of Angelica gigas root on receptor activator of nuclear factor kappa B ligand (RANKL)-induced osteoclast formation using mouse bone marrow-derived macrophages (BMMs). Decursin inhibited RANKL-induced osteoclast formation without cytotoxicity. In particular, decursin maintains the characteristics of macrophages by blocking osteoclast differentiation by RANKL. Furthermore, the RANKL-stimulated bone resorption was diminished by decursin. Mechanistically, decursin blocked the RANKL-triggered ERK mitogen-activated protein kinases (MAPK) phosphorylation, which results in suppression of c-Fos and the nuclear factor of activated T cells (NFATc1) expression. In accordance with the in vitro study, decursin reduced lipopolysaccharide (LPS)- or ovariectomy (OVX)-induced bone loss in vivo. Therefore, decursin exerted an inhibitory effect on osteoclast formation and bone loss in vitro and in vivo. Decursin could be useful for the treatment of bone diseases associated with excessive bone resorption.
References
Oct 21, 1994·Science·A E GrigoriadisE F Wagner
Oct 17, 1998·Immunopharmacology·S B HanH M Kim
Jun 16, 1999·Endocrine Reviews·T SudaT J Martin
Sep 29, 1999·Genes & Development·W C DougallJ Schuh
Dec 14, 2002·Developmental Cell·Hiroshi TakayanagiTadatsugu Taniguchi
May 16, 2003·Nature·William J BoyleDavid L Lacey
Mar 31, 2004·Molecular Aspects of Medicine·Virginia B C JunqueiraGuilherme P Deucher
Apr 10, 2004·The Journal of Biological Chemistry·Koichi MatsuoErwin F Wagner
Aug 18, 2004·The Journal of Clinical Investigation·Fumiyo IkedaToshiyuki Yoneda
Nov 9, 2004·Experimental Cell Research·Hyunil HaZang Hee Lee
Jan 26, 2005·The Journal of Clinical Investigation·Shi WeiSteven L Teitelbaum
Feb 23, 2005·Current Drug Targets. CNS and Neurological Disorders·James W SimpkinsJames A Dykens
Jul 14, 2005·IUBMB Life·Xu Feng
Aug 17, 2005·Current Drug Targets. Inflammation and Allergy·Yoshiya TanakaYosuke Okada
Aug 20, 2005·The Journal of Biological Chemistry·Kabsun KimNacksung Kim
Jan 7, 2006·Cancer Research·Cheng JiangJunxuan Lu
Nov 14, 2006·Bone·Masataka Asagiri, Hiroshi Takayanagi
Mar 24, 2007·Nature Reviews. Immunology·Hiroshi Takayanagi
Apr 4, 2007·The Journal of Biological Chemistry·Sudarshana M SharmaMichael C Ostrowski
Nov 13, 2007·Journal of Pharmaceutical and Biomedical Analysis·Mi-Jeong AhnSang Hyun Sung
Nov 28, 2007·Annual Review of Pathology·Deborah V Novack, Steven L Teitelbaum
Dec 17, 2008·Annals of the New York Academy of Sciences·Andreas Leibbrandt, Josef M Penninger
Mar 3, 2009·Biological & Pharmaceutical Bulletin·Eun Ju YangIn Sik Kim
Mar 4, 2010·International Journal of Molecular Medicine·Wun-Jae KimSung-Kwon Moon
Oct 6, 2011·Phytotherapy Research : PTR·Jin-Taek HwangDae Young Kwon
Jun 1, 2014·Life Sciences·Young Ji ChoiSeon-Young Kim
Citations
Jan 23, 2017·International Journal of Biological Macromolecules·Hyun Woo LeeHoon Kim
Apr 18, 2018·Journal of Cellular Physiology·Ji-Jun ZhaoLi Cheng
Jan 20, 2018·Evidence-based Complementary and Alternative Medicine : ECAM·Hye Won LeeSunmin Park
Sep 8, 2017·Cell Death & Disease·Xiao ChenJiacan Su
Jan 5, 2020·Psychopharmacology·Li MaXin Zhao
May 23, 2020·Neurochemical Research·Jong Min OhHoon Kim
Jul 20, 2018·BMC Complementary and Alternative Medicine·Seo Hyun KimSung Ho Jeon
Nov 15, 2017·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·Adeeb ShehzadYoung Sup Lee
Feb 9, 2021·Fitoterapia·Samia Jessica Silva Tavares, Vilma Lima
Apr 13, 2021·Frontiers in Pharmacology·La Yoon ChoiWoong Mo Yang
Jun 13, 2021·Journal of Pharmacological Sciences·Dingwei CangBiao Ji